Vieira Roberto Wandenkolk's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Sep 3, 2026
- Accession no.
- 0001193125-26-382456
- Filed
- Sep 3, 2026, 9:02 PM ET
- Trade date
- Sep 1-2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 11 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.46M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vieira Roberto WandenkolkCIK 0002150104 | Officer (President, Oncology) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Common Stock | AGrant or awardAcquired | +138 | $113.38F2 | +$15,646.44 | 4,206 | Direct | |
| Sep 1, 2026 | Common Stock | AGrant or awardAcquired | +138 | $0.00 | $0 | 4,344 | Direct | |
| Sep 2, 2026 | Common Stock | FTax withholdingDisposed | −102 | $113.38F6 | −$11,564.76 | 4,242 | Direct | |
| Sep 2, 2026 | Common Stock | MOption exerciseAcquired | +58,333 | $21.63 | +$1,261,742.79 | 62,575 | Direct | |
| Sep 2, 2026 | Common Stock | SSaleDisposed | −23,600 | $109.35F9 | −$2,580,674.16 | 38,975 | Direct | |
| Sep 2, 2026 | Common Stock | SSaleDisposed | −23,770 | $110.70F10 | −$2,631,348.51 | 15,205 | Direct | |
| Sep 2, 2026 | Common Stock | SSaleDisposed | −1,537 | $111.37F11 | −$171,180.76 | 13,668 | Direct | |
| Sep 2, 2026 | Common Stock | SSaleDisposed | −974 | $112.40F12 | −$109,474.29 | 12,694 | Direct | |
| Sep 2, 2026 | Common Stock | SSaleDisposed | −1,606 | $113.72F13 | −$182,632.23 | 11,088 | Direct | |
| Sep 2, 2026 | Common Stock | SSaleDisposed | −5,621 | $114.58F14 | −$644,042.38 | 5,467 | Direct | |
| Sep 2, 2026 | Common Stock | SSaleDisposed | −1,225 | $115.44F15 | −$141,413.39 | 4,242 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Common Stock | MOption exerciseDisposed | −58,333 | $0.00 | $0 | 141,667 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
- F6
The closing price on September 1, 2026 was used to calculate the withholding obligation.
Referenced by the price of 1 transaction in Table I.
- F9
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F10
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F11
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F12
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F13
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F14
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F15
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.